Acumen Pharmaceuticals announced the completion of enrollment in its Phase 2 ALTITUDE-AD clinical trial for sabirnetug (ACU193) in patients with early Alzheimer’s disease. This achievement was completed ahead of schedule, demonstrating strong operational execution.
The ALTITUDE-AD trial is a randomized, double-blind, placebo-controlled, three-arm study designed to evaluate the clinical efficacy and safety of sabirnetug in up to 540 participants. The primary endpoint is the change from baseline to 18 months on the Integrated Alzheimer’s Disease Rating Scale (iADRS).
The company plans to report topline results, including safety and efficacy data, in late 2026. Completing enrollment ahead of schedule is a critical milestone that de-risks the timeline to this major value inflection point for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.